Managing Acute Heavy Menstrual Bleeding in the Office Setting

Question: I am used to treating patients who report chronic heavy menstrual bleeding, but what can I do for a patient in my clinic who at this moment is actively losing excessive amounts of blood? She has to change her pad every 30-40 minutes and wear double protection to prevent spillage. I can tell she needs help now and may not be able to be referred.

Acute heavy menstrual bleeding (HMB) is most often seen in Emergency Room settings. Sometimes patients actually delay their clinic visits because of acute bleeding due to the pain and challenges posed by traveling and maintaining personal hygiene. Regardless of where you see them—in your office, in an urgent care setting, even in an ER—the initial work-up is the same, advises Anita Nelson, MD.

Here’s what to do:

Acute heavy menstrual bleeding management: initial workup and when to escalate

Regardless of the setting—office, urgent care, or ED—the initial workup is the same:

• Assess hemodynamic stability first. Check symptoms and vital signs (are there any orthostatic changes?).
• Rule out pregnancy with a urine pregnancy test.
• Check a hemoglobin/hematocrit to rule out anemia. Outpatient management requires a hemoglobin above 8 g/dL. Below that, escalate.
• Review medications, anticoagulants in particular.
• Take a focused menstrual history. Ask about prior episodes, past work-ups, prior treatments (and whether they worked), and any history of cancer.
• Perform a targeted physical exam. Start with the abdomen and a bimanual exam—assess for an enlarged or irregularly shaped uterus. Follow with a pelvic exam to rule out less common but important causes: aborting fibroid, trauma, known carcinoma, foreign body.

Once you’ve ruled out conditions requiring immediate procedural intervention, the good news is that most episodes of acute excessive bleeding will respond very well to hormonal therapies.

Treatment goals: stop bleeding and prevent recurrence

As you think about the best treatment option to offer, it helps to remember that the treatment must not only be able to safely stop the immediate bleeding, but also to prevent any more bleeding for 4 weeks. This time is needed for the patient to rebuild their hemoglobin and for the provider to obtain the results of any tests that were performed to help diagnose the cause of the abnormal bleeding so more targeted long-term plans can be designed.

First-line management: high-dose MPA regimen

The most effective, well-tolerated regimen is medroxyprogesterone acetate (MPA):

• MPA 20 mg orally three times daily × 7 days, then
• MPA 20 mg orally once daily × 3 months

This regimen stops bleeding rapidly, typically induces amenorrhea for at least 28 days, and contains no estrogen. Importantly, MPA is not metabolized into estrogen the way some other progestins are (e.g., norethindrone acetate), which minimizes thromboembolic risk. Studies show that this high-dose treatment is also well-tolerated.

A note on lower-dose protocols: Shorter or lower-dose progestin regimens are commonly offered but aren’t supported by evidence. MPA 10 mg daily for 10 days —one of the most frequently recommended alternatives —often leads to rebleeding within 3 days of stopping. If the goal is to stop bleeding and maintain control for a month, this approach frequently falls short.

COCs in acute heavy menstrual bleeding management: what works and what to avoid

In some settings, combined oral contraceptives (COCs) are part of the acute management plan. If you go this route:

• Avoid excessively high doses
• Avoid rapid “tapering” regimens, which frequently trigger rebleeding as the dose drops

Any pill with 1 mg norethindrone and 35 mcg ethinyl estradiol (EE) can be used in either of these regimens.

• 1/35 pill with norethindrone and EE given orally, 3 times a day for 7 days, followed by a 1/20 norethindrone and EE pill once a day for the next 21 days.

OR

• 1/35 pill with norethindrone and EE given orally every 12 hours for 2 doses, followed by 1 pill daily for the rest of the pill packet.

There is no need to use higher doses of oral contraceptives initially, as it increases VTE risk. Similarly, more rapid “tapering” can induce repeat abnormal bleeding. The first option was tested and published against the MPA-only protocol. The second option —a single day, higher dose with normal dose for the subsequent 26 days —was recommended in recent textbooks.

Key takeaways

• Acute HMB can and does show up in the office—the initial workup is the same regardless of setting.
• A hemoglobin above 8 g/dL is required for outpatient management; escalate if below.
• High-dose MPA (20 mg TID × 7 days, then 20 mg daily × 3 months) is the most evidence-based option—it stops bleeding and prevents recurrence for the window needed to plan next steps.
• Lower-dose or shorter progestin courses are common but often fail to achieve both treatment goals.
• If using COCs, avoid dose tapering strategies that trigger rebound bleeding.